Adam Hacker is the Chair of the MHRA Review Panel at Medicines and Healthcare products Regulatory Agency. Prior to this role, Adam held positions such as Head of Global Regulatory Affairs and Quality at CEPI, SVP Global Head Regulatory Affairs and Quality at Autolus Ltd., and various leadership roles at The Janssen Pharmaceutical Companies of Johnson & Johnson, Johnson and Johnson, Biogen Idec, Amersham Health, and GlaxoSmithKline. Adam has a PhD in Molecular Developmental Biology from the National Institute for Medical Research and a BA Hon in Pure and Applied Biology from the University of Oxford.
This person is not in any teams
This person is not in any offices
CEPI (Coalition for Epidemic Preparedness Innovations)
1 followers
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X). During the COVID-19 pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale, and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX. CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at www.endpandemics.cepi.net